Research Progress of Microbiota and Fecal Transplantation

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Gastroenterology & Hepatology".

Deadline for manuscript submissions: closed (31 July 2022) | Viewed by 14044

Special Issue Editors


E-Mail
Guest Editor

Special Issue Information

Dear Colleagues,

The gut microbiota plays a pivotal role in the maintenance of human health. The disequilibrium of its composition is involved in the onset and progression of several human diseases. Recently, new insights regarding the mechanisms of the host–microbiota relationship have been described. Fecal microbiota transplantation is the transfer of fecal material from a healthy donor into the intestinal tract of a patient in order to directly change the microbial composition of the recipient's gut with the aim of inducing health benefits. Fecal microbiota transplantation has been proposed to successfully treat recurrent Clostridium difficile infections. However, some data indicate that it may also be applied to treat other digestive disorders including inflammatory bowel disease, functional gastrointestinal disorders, food allergies, obesity, and liver diseases.

The journal Medicina is launching a Special Issue entitled Research Progress of Microbiota and Fecal Transplantation that aims to discuss the current evidence and to explore potential future research directions in this field. We are pleased to invite you and your colleagues to submit your original articles, from basic to clinical research, including comprehensive reviews, that explore new issues in the field of human gut microbiota and the safety, efficacy, and application of fecal microbiota transplantation.

Dr. Ludovico Abenavoli
Dr. Emdio Scarpellini
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gastrointestinal tract
  • microbiome
  • metabolism
  • obesity
  • liver disease
  • research
  • nutrition
  • therapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

11 pages, 728 KiB  
Review
Fecal Microbiota Transplantation in NAFLD Treatment
by Ludovico Abenavoli, Valentina Maurizi, Emanuele Rinninella, Jan Tack, Arianna Di Berardino, Pierangelo Santori, Carlo Rasetti, Anna Caterina Procopio, Luigi Boccuto and Emidio Scarpellini
Medicina 2022, 58(11), 1559; https://doi.org/10.3390/medicina58111559 - 30 Oct 2022
Cited by 27 | Viewed by 4292
Abstract
Introduction: Gut microbiota is not only a taxonomic biologic ecosystem but is also involved in human intestinal and extra-intestinal functions such as immune system modulation, nutrient absorption and digestion, as well as metabolism regulation. The latter is strictly linked to non-alcoholic fatty [...] Read more.
Introduction: Gut microbiota is not only a taxonomic biologic ecosystem but is also involved in human intestinal and extra-intestinal functions such as immune system modulation, nutrient absorption and digestion, as well as metabolism regulation. The latter is strictly linked to non-alcoholic fatty liver disease (NAFLD) pathophysiology. Materials and methods: We reviewed the literature on the definition of gut microbiota, the concepts of “dysbiosis” and “eubiosis”, their role in NAFLD pathogenesis, and the data on fecal microbiota transplantation (FMT) in these patients. We consulted the main medical databases using the following keywords, acronyms, and their associations: gut microbiota, eubiosis, dysbiosis, bile acids, NAFLD, and FMT. Results: Gut microbiota qualitative and quantitative composition is different in healthy subjects vs. NALFD patients. This dysbiosis is associated with and involved in NAFLD pathogenesis and evolution to non-acoholic steatohepatitis (NASH), liver cirrhosis, and hepatocellular carcinoma (HCC). In detail, microbial-driven metabolism of bile acids (BAs) and interaction with hepatic and intestinal farnesoid nuclear X receptor (FXR) have shown a determinant role in liver fat deposition and the development of fibrosis. Over the use of pre- or probiotics, FMT has shown preclinical and initial clinical promising results in NAFLD treatment through re-modulation of microbial dysbiosis. Conclusions: Promising clinical data support a larger investigation of gut microbiota dysbiosis reversion through FMT in NAFLD using randomized clinical trials to design precision-medicine treatments for these patients at different disease stages. Full article
(This article belongs to the Special Issue Research Progress of Microbiota and Fecal Transplantation)
Show Figures

Figure 1

13 pages, 344 KiB  
Review
A Retrospective Narrative Mini-Review Regarding the Seminal Microbiota in Infertile Male
by Bogdan Doroftei, Ovidiu-Dumitru Ilie, Ana-Maria Dabuleanu, Delia Hutanu and Constantin-Cristian Vaduva
Medicina 2022, 58(8), 1067; https://doi.org/10.3390/medicina58081067 - 7 Aug 2022
Cited by 3 | Viewed by 2898
Abstract
Background: Infertility is a global burden that affects both sexes with the male component remaining as an explored yet crucial research field that might offer novel evidence. Material and Methods: The present narrative mini-review aims to summarize all existing literature regarding [...] Read more.
Background: Infertility is a global burden that affects both sexes with the male component remaining as an explored yet crucial research field that might offer novel evidence. Material and Methods: The present narrative mini-review aims to summarize all existing literature regarding the composition of the seminal microflora in infertile men. We performed searches in PubMed/Medline, ISI Web of Knowledge, Scopus, and ScienceDirect between 2018 and 2022 using a combination of keywords. Results: A total of n = 33 studies met the eligibility criteria and were further considered. From this, n = 14 were conducted on human patients, n = 3 on zebrafish (Danio rerio), n = 5 on rats, and n = 11 on mice. In twenty-five out of thirty-three papers, the authors sequenced the 16S rRNA; situations occurred where researchers focused on standard laboratory protocols. Lactobacillus and Bifidobacterium are widely recognized as putative beneficial lactic bacteria. These two entities are capable of restoring the host’s eubiosis to some extent, blocking pathogens’ proliferation and endotoxins, and even alleviating specific patterns encountered in disease(s) (e.g., obesity, type 1 diabetes) due to prolonged exposure to toxicants in adults or from a developmental stage. Over the years, distinct approaches have been perfected, such as the transfer of feces between two species or conventional rudimentary products with proven efficiency. Conclusions: The seminal microflora is decisive and able to modulate psychological and physiological responses. Each individual possesses a personalized microbial profile further shaped by exogenous factors, regardless of sex and species. Full article
(This article belongs to the Special Issue Research Progress of Microbiota and Fecal Transplantation)
24 pages, 882 KiB  
Review
Current Status and Future Therapeutic Options for Fecal Microbiota Transplantation
by Sergii Tkach, Andrii Dorofeyev, Iurii Kuzenko, Nadiya Boyko, Tetyana Falalyeyeva, Luigi Boccuto, Emidio Scarpellini, Nazarii Kobyliak and Ludovico Abenavoli
Medicina 2022, 58(1), 84; https://doi.org/10.3390/medicina58010084 - 6 Jan 2022
Cited by 24 | Viewed by 5951
Abstract
The intestinal microbiota plays an important role in maintaining human health, and its alteration is now associated with the development of various gastrointestinal (ulcerative colitis, irritable bowel syndrome, constipation, etc.) and extraintestinal diseases, such as cancer, metabolic syndrome, neuropsychiatric diseases. In this context, [...] Read more.
The intestinal microbiota plays an important role in maintaining human health, and its alteration is now associated with the development of various gastrointestinal (ulcerative colitis, irritable bowel syndrome, constipation, etc.) and extraintestinal diseases, such as cancer, metabolic syndrome, neuropsychiatric diseases. In this context, it is not surprising that gut microbiota modification methods may constitute a therapy whose potential has not yet been fully investigated. In this regard, the most interesting method is thought to be fecal microbiota transplantation, which consists of the simultaneous replacement of the intestinal microbiota of a sick recipient with fecal material from a healthy donor. This review summarizes the most interesting findings on the application of fecal microbiota transplantation in gastrointestinal and extraintestinal pathologies. Full article
(This article belongs to the Special Issue Research Progress of Microbiota and Fecal Transplantation)
Show Figures

Figure 1

Back to TopTop